GSK Malarone safety profile
Executive Summary
Safety data comparing GlaxoSmithKline's Malarone (atovaquone/proguanil) to older antimalarials approved for Malarone label, GSK said Aug. 22. In clinical studies, patients taking Malarone had fewer neuropsychiatric side effects than Roche's Lariam (mefloquine) (14% vs. 29%) and fewer gastrointestinal events than patients receiving chloroquine/proguanil (12% vs. 20%)...